FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W48495299> ?p ?o ?g. }

• W48495299 endingPage "1542" @default.
• W48495299 startingPage "1534" @default.
• W48495299 abstract "Abstract In the present study, we investigated the ability of the tetrapeptide NAc-Ser-Asp-Lys-Pro-OH (AcSDKP), a reported inhibitor of primitive hematopoietic cells, to influence the proliferative behavior of primitive normal and chronic myeloid leukemia (CML) progenitor cells in the adherent layer of long-term cultures (LTCs). Addition of > or = 50 ng/mL of AcSDKP to LTCs of normal cells at the time of the regular weekly half-medium change selectively and reversibly decreased the proportion of high proliferative potential erythroid and granulopoietic progenitors in the adherent layer that were in S-phase without changing their numbers, but had no effect on either the cycling activity or number of analogous (neoplastic) cells in the adherent layer of CML LTCs. Specificity of the effect of AcSDKP on primitive normal progenitors was demonstrated by the finding that a similar addition of either the control peptide, AcSDKE, or 100 ng/mL of tumor necrosis factor-alpha (TNF-alpha, which contains the SDKP sequence), or SDKP itself (at 300 ng/mL) did not inhibit the proliferation of primitive normal progenitors in LTC adherent layers. Incorporation of > or = 30 ng/mL of AcSDKP (but not the related control peptide, AcSDKE) directly into methylcellulose cultures of normal marrow cells resulted in a dose- dependent suppression of colony formation, which was not seen in similar studies with CML marrow or after removal of adherent cells from normal marrow. Additional experiments showed that the inhibitory effect of AcSDKP on primitive normal progenitor cycling in the LTC system could be overcome by the simultaneous addition of macrophage inflammatory protein-1 beta (MIP-1 beta); an antagonist of MIP-1 alpha. The apparent differential effect of AcSDKP on primitive normal and CML progenitors may thus be a secondary consequence of the differential responsiveness of these cells to MIP-1 alpha for another molecule antagonized by MIP-1 beta), whose production or release by adherent marrow cells is inducible by AcSDKP. Such a mechanism may offer a method for obtaining localized increases in vivo of cytokines like MIP- 1 alpha, suggesting novel and perhaps less toxic strategies for protecting primitive normal progenitors during repeated treatments with cycle-active chemotherapeutic agents where escalating the dose of drug given would be desirable." @default.
• W48495299 created "2016-06-24" @default.
• W48495299 creator A5010934655 @default.
• W48495299 creator A5064802942 @default.
• W48495299 creator A5087731631 @default.
• W48495299 date "1994-09-01" @default.
• W48495299 modified "2023-10-18" @default.
• W48495299 title "The tetrapeptide AcSDKP specifically blocks the cycling of primitive normal but not leukemic progenitors in long-term culture: evidence for an indirect mechanism" @default.
• W48495299 cites W106629669 @default.
• W48495299 cites W129232635 @default.
• W48495299 cites W153768115 @default.
• W48495299 cites W1538762819 @default.
• W48495299 cites W1558296954 @default.
• W48495299 cites W1572034510 @default.
• W48495299 cites W1669948635 @default.
• W48495299 cites W1836124358 @default.
• W48495299 cites W1990906025 @default.
• W48495299 cites W2014995072 @default.
• W48495299 cites W2016234421 @default.
• W48495299 cites W2030641259 @default.
• W48495299 cites W2037045407 @default.
• W48495299 cites W2053412433 @default.
• W48495299 cites W2059067233 @default.
• W48495299 cites W2060892787 @default.
• W48495299 cites W2062310322 @default.
• W48495299 cites W2106883237 @default.
• W48495299 cites W2118024162 @default.
• W48495299 cites W2149604229 @default.
• W48495299 cites W226271522 @default.
• W48495299 cites W2306715427 @default.
• W48495299 cites W233116989 @default.
• W48495299 cites W2400107473 @default.
• W48495299 cites W2401355733 @default.
• W48495299 cites W2403984936 @default.
• W48495299 cites W2404585250 @default.
• W48495299 cites W2409677275 @default.
• W48495299 cites W2410919774 @default.
• W48495299 cites W2411065622 @default.
• W48495299 cites W2412477990 @default.
• W48495299 cites W2413607152 @default.
• W48495299 cites W2414951805 @default.
• W48495299 cites W2416128265 @default.
• W48495299 cites W2418848010 @default.
• W48495299 cites W2430972769 @default.
• W48495299 cites W2442413634 @default.
• W48495299 cites W2464432956 @default.
• W48495299 cites W273564206 @default.
• W48495299 cites W72367593 @default.
• W48495299 cites W2441379453 @default.
• W48495299 doi "https://doi.org/10.1182/blood.v84.5.1534.1534" @default.
• W48495299 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8068944" @default.
• W48495299 hasPublicationYear "1994" @default.
• W48495299 type Work @default.
• W48495299 sameAs 48495299 @default.
• W48495299 citedByCount "51" @default.
• W48495299 countsByYear W484952992013 @default.
• W48495299 countsByYear W484952992014 @default.
• W48495299 countsByYear W484952992015 @default.
• W48495299 crossrefType "journal-article" @default.
• W48495299 hasAuthorship W48495299A5010934655 @default.
• W48495299 hasAuthorship W48495299A5064802942 @default.
• W48495299 hasAuthorship W48495299A5087731631 @default.
• W48495299 hasBestOaLocation W484952991 @default.
• W48495299 hasConcept C109159458 @default.
• W48495299 hasConcept C126322002 @default.
• W48495299 hasConcept C134018914 @default.
• W48495299 hasConcept C153911025 @default.
• W48495299 hasConcept C15729860 @default.
• W48495299 hasConcept C185592680 @default.
• W48495299 hasConcept C201750760 @default.
• W48495299 hasConcept C2779281246 @default.
• W48495299 hasConcept C2779564779 @default.
• W48495299 hasConcept C28328180 @default.
• W48495299 hasConcept C55493867 @default.
• W48495299 hasConcept C71924100 @default.
• W48495299 hasConcept C86803240 @default.
• W48495299 hasConcept C95444343 @default.
• W48495299 hasConceptScore W48495299C109159458 @default.
• W48495299 hasConceptScore W48495299C126322002 @default.
• W48495299 hasConceptScore W48495299C134018914 @default.
• W48495299 hasConceptScore W48495299C153911025 @default.
• W48495299 hasConceptScore W48495299C15729860 @default.
• W48495299 hasConceptScore W48495299C185592680 @default.
• W48495299 hasConceptScore W48495299C201750760 @default.
• W48495299 hasConceptScore W48495299C2779281246 @default.
• W48495299 hasConceptScore W48495299C2779564779 @default.
• W48495299 hasConceptScore W48495299C28328180 @default.
• W48495299 hasConceptScore W48495299C55493867 @default.
• W48495299 hasConceptScore W48495299C71924100 @default.
• W48495299 hasConceptScore W48495299C86803240 @default.
• W48495299 hasConceptScore W48495299C95444343 @default.
• W48495299 hasIssue "5" @default.
• W48495299 hasLocation W484952991 @default.
• W48495299 hasOpenAccess W48495299 @default.
• W48495299 hasPrimaryLocation W484952991 @default.
• W48495299 hasRelatedWork W1877475121 @default.
• W48495299 hasRelatedWork W2004654204 @default.
• W48495299 hasRelatedWork W2060471375 @default.

• next